Ligand buys royalty rights in pharmaceutical products and earns income from its Captisol and NITRICIL technology platforms. Analyst consensus is Strong Buy, based on the latest ratings from 6 firms (6 buy, 0 hold, 0 sell).
Analyst Ratings & Price Targets
Analyst Ratings →| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Oct 30 | RBC Capital | Target raised | Buy | |
| Sep 25 | Barclays | Initiated | Buy | |
| Sep 23 | Citigroup | Target raised | Buy | |
| Aug 14 | Leerink Partners | Initiated | Buy | |
| Aug 7 | RBC Capital | Target raised | Buy |
Whale Options Flow
90DNo whale options trades in LGND in the last 90 days.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether LGND is in one of them and how their past LGND trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered LGND in an article yet. Here's the latest on the wider market.
LGND Congress Trades
All congress trades →
| Person | Type | Amount | Traded | Filed | Delay |
|---|---|---|---|---|---|
| Donald J TrumpExecutive branch | Sell | $15K – $50K | May 15, 2026 | Jul 1, 2026 | 47 d |
| Gilbert CisnerosD · CA | Buy | $1K – $15K | May 29, 2026 | Jun 8, 2026 | 10 d |
| Gilbert CisnerosD · CA | Buy | $1K – $15K | Mar 3, 2026 | Apr 7, 2026 | 35 d |
| Gilbert CisnerosD · CA | Buy | $1K – $15K | Jan 15, 2026 | Feb 13, 2026 | 29 d |
| Gilbert CisnerosD · CA | Buy | $1K – $15K | Jan 5, 2026 | Feb 13, 2026 | 39 d |
Members of Congress and senior officials report trades up to 45 days later, as dollar ranges. Filings show a trade happened, not why. Not investment advice.
About Ligand Pharmaceuticals
Ligand is a biopharmaceutical royalty company based in San Diego, California. It buys and structures royalty interests in medicines that are in clinical development or already on the market, earning income from sales made by partner drugmakers. It also earns royalties and material sales from its Captisol and NITRICIL technology platforms. Its customers are mainly biopharmaceutical companies that develop and sell the medicines tied to its royalty streams.
- Headquarters
- San Diego, CA